全文获取类型
收费全文 | 31717篇 |
免费 | 1824篇 |
国内免费 | 151篇 |
专业分类
耳鼻咽喉 | 292篇 |
儿科学 | 423篇 |
妇产科学 | 346篇 |
基础医学 | 4253篇 |
口腔科学 | 982篇 |
临床医学 | 2072篇 |
内科学 | 7565篇 |
皮肤病学 | 848篇 |
神经病学 | 2253篇 |
特种医学 | 1269篇 |
外科学 | 5548篇 |
综合类 | 154篇 |
一般理论 | 1篇 |
预防医学 | 989篇 |
眼科学 | 644篇 |
药学 | 2438篇 |
中国医学 | 44篇 |
肿瘤学 | 3571篇 |
出版年
2022年 | 242篇 |
2021年 | 543篇 |
2020年 | 326篇 |
2019年 | 398篇 |
2018年 | 520篇 |
2017年 | 479篇 |
2016年 | 509篇 |
2015年 | 549篇 |
2014年 | 715篇 |
2013年 | 904篇 |
2012年 | 1345篇 |
2011年 | 1476篇 |
2010年 | 867篇 |
2009年 | 783篇 |
2008年 | 1317篇 |
2007年 | 1316篇 |
2006年 | 1348篇 |
2005年 | 1438篇 |
2004年 | 1333篇 |
2003年 | 1351篇 |
2002年 | 1280篇 |
2001年 | 1291篇 |
2000年 | 1326篇 |
1999年 | 1197篇 |
1998年 | 396篇 |
1997年 | 336篇 |
1996年 | 302篇 |
1995年 | 282篇 |
1994年 | 245篇 |
1993年 | 238篇 |
1992年 | 820篇 |
1991年 | 724篇 |
1990年 | 732篇 |
1989年 | 698篇 |
1988年 | 711篇 |
1987年 | 622篇 |
1986年 | 613篇 |
1985年 | 597篇 |
1984年 | 392篇 |
1983年 | 323篇 |
1982年 | 149篇 |
1980年 | 134篇 |
1979年 | 319篇 |
1978年 | 204篇 |
1977年 | 151篇 |
1975年 | 149篇 |
1974年 | 213篇 |
1973年 | 151篇 |
1972年 | 165篇 |
1971年 | 147篇 |
排序方式: 共有10000条查询结果,搜索用时 390 毫秒
991.
Junya Yamamoto Daigo Nakazawa Saori Nishio Yasunobu Ishikawa Minoru Makita Yoshihiro Kusunoki So Nagai Yuichiro Fujieda Masahiko Takahata Kanji Yamada Tsuyoshi Yamamura Akihiko Yotsukura Masanobu Saito Masaru Shimazaki Tatsuya Atsumi 《Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy》2020,24(2):146-153
Adynamic bone disease in HD patients is characterized by skeletal resistance to parathyroid hormone (PTH) or suppression of PTH release, leading to a downregulated bone turnover and bone fracture. Hence, we examined the efficacy of weekly teriparatide for HD patients with low PTH indicating adynamic bone disease without a history of parathyroidectomy. Fifteen HD patients with low PTH were recruited in this prospective observational study. Of them, 10 received teriparatide for 12 months and five nontreated patients were enrolled as control. Primary outcomes were defined as the changes in bone mineral density and bone turnover markers. Bone mineral density at the lumbar spine increased by 3.7% and 2.5% at 6 and 12 months, respectively, and bone formation markers increased, while bone resorption markers did not change in the teriparatide group. At 12 months after teriparatide administration, endogenous PTH was secreted followed by the recovery of low bone turnover. 40% of patients in the teriparatide group dropped out due to adverse events and the most common adverse event was transient hypotension. This study suggests that weekly teriparatide for HD patients with low PTH in the absence of parathyroidectomy accelerates bone formation and bone turnover, leading to increased trabecular bone mass and secretion of endogenous PTH. 相似文献
992.
Kimio Sugaya Saori Nishijima Katsumi Kadekawa Katsuhiko Noguchi Tomoyuki Ueda Hideyuki Yamamoto 《Lower urinary tract symptoms.》2020,12(1):92-98
The effects of solifenacin and mirabegron on vesical and urethral function were compared in rats with or without spinal cord injury (SCI). Isovolumetric cystometry and urethral pressure recording were initially performed in intact rats. Then, the bladder neck was ligated under urethane anesthesia, after which a catheter was inserted through the bladder dome for isovolumetric cystometry and another catheter was inserted into the urethra to measure urethral pressure. Solifenacin (0.03–3 mg/kg) or mirabegron (0.03–3 mg/kg) was injected intravenously, and bladder and urethral activity were recorded. To create rats with SCI, the spinal cord was transected at the lower thoracic level under isoflurane anesthesia. After 2 weeks, a catheter was inserted through the bladder dome for single cystometry and bladder activity was recorded without anesthesia following intravenous injection of solifenacin or mirabegron. Isovolumetric cystometry revealed a larger decrease in maximum bladder contraction pressure after injection of solifenacin, whereas prolongation of the interval between bladder contractions was greater with mirabegron. In SCI rats, single cystometry showed that solifenacin and mirabegron both increased bladder volume at the first non‐voiding bladder contraction and decreased the maximum bladder contraction pressure. Mirabegron also increased the voided volume and decreased the percentage residual volume without altering bladder capacity. Solifenacin and mirabegron both inhibited bladder contractility, and mirabegron possibly also induced urethral relaxation. Mirabegron may be suitable for patients with overactive bladder and residual urine. 相似文献
993.
Nobuaki Sakamoto Huanhuan Hu Akiko Nanri Tetsuya Mizoue Masafumi Eguchi Takeshi Kochi Tohru Nakagawa Toru Honda Shuichiro Yamamoto Takayuki Ogasawara Naoko Sasaki Akiko Nishihara Teppei Imai Toshiaki Miyamoto Makoto Yamamoto Hiroko Okazaki Kentaro Tomita Akihiko Uehara Ai Hori Makiko Shimizu Taizo Murakami Keisuke Kuwahara Ami Fukunaga Isamu Kabe Tomofumi Sone Seitaro Dohi 《Journal of diabetes investigation.》2020,11(3):719-725
994.
995.
996.
Yosuke Omori Toshiaki Mano Tomohito Ohtani Yasushi Sakata Yasuharu Takeda Shunsuke Tamaki Yasumasa Tsukamoto Takeshi Miwa Kazuhiro Yamamoto Issei Komuro 《Yonago acta medica》2014,57(3):109-116
Background
Cardiac fibrosis is considered to be a crucial factor in the development of heart failure. Blockade of the mineralocorticoid receptor (MR) attenuated cardiac fibrosis and improved the prognosis of patients with chronic heart failure but the ligand for MR and the regulatory mechanism of MR pathway in the diseased heart are unclear. Here, we investigated whether glucocorticoids can promote cardiac fibrosis through MR in oxidative stress and the involvement of elongation factor eleven-nineteen lysine-rich leukemia (ELL), a co-activator of MR, in this pathway.Methods and Results
The MR antagonist eplerenone attenuated corticosterone-induced collagen synthesis assessed by [3H]proline incorporation in rat neonatal cultured cardiac fibroblasts in the presence of H2O2, as an oxidative stress but not in the absence of H2O2. H2O2 increased the ELL expression levels and MR-bound ELL. ELL expression levels and MR-bound ELL were also increased in the left ventricle of heart failure model rats with significant fibrosis and enhanced oxidative stress. Eplerenone did not attenuate corticosterone-induced increase of [3H]proline incorporation in the presence of H2O2 after knockdown of ELL expression using small interfering RNA in cardiac fibroblasts.Conclusion
Glucocorticoids can promote cardiac fibrosis via MR in oxidative stress, and oxidative stress modulates MR response to glucocorticoids through the interaction with ELL. Preventing cardiac fibrosis by modulating glucocorticoid-MR-ELL pathway may become a new therapeutic strategy for heart failure. 相似文献997.
998.
Eleanor L. Menzies John R.H. Archer Paul I. Dargan Mark C. Parkin Takahiro Yamamoto David M. Wood Robin A. Braithwaite Simon P. Elliott Andrew T. Kicman 《Drug testing and analysis》2019,11(9):1419-1430
The disposition of drugs and their metabolites have been extensively described in the literature, based primarily on the analysis of plasma and urine. However, there are more limited data on their disposition in whole blood, which is often the only specimen available in forensic investigations and cases of driving under the influence of drugs. In this study, we have, for the first time, established pharmacokinetic properties of cocaine (COC) and its metabolites from concurrently collected whole blood and plasma samples, following a single 100 mg dose of cocaine hydrochloride administered via nasal insufflation to seven healthy volunteers. The median Cmax of COC and its major metabolites, benzoylecgonine (BZE) and ecgonine methyl ester (EME), were closely related in whole blood and plasma. The median Cmax for COC in plasma was 379.7 ng/mL (347.5–517.7) and 344.24 ng/mL (271.6–583.2) in whole blood. The median Cmax for BZE in plasma was 441.2 ng/mL (393.6–475. and 371.18 ng/mL (371.1–477.3) in whole blood, EME was 105.5 ng/mL (93.6–151.8) in plasma and 135.5 ng/mL (87.8–183) in whole blood. Calculated medians of the whole blood to plasma ratio of COC (0.76), BZE (0.98) and EME (1.02) of approximately 1, strongly suggesting that the erythrocyte cell wall presents no barrier to COC and its metabolites. Furthermore, whole blood and plasma concentrations of COC were strongly correlated (R2 = 0.0914 R = 0.956, p < 0.0001), as was BZE (R2 = 0.0932 R = 0.965, p < 0.0001) and EME (R2 = 0.0964R = 0.928, p < 0.0001). The minor oxidative metabolite norcocaine (NCOC) was detected in both whole blood and plasma at concentrations between 1 and 5 ng/mL within 60–180 minutes, suggesting that NCOC could be indicator of recent COC administration. Data from this study have shown for the first time that COC and its metabolites BZE and EME are evenly distributed between plasma and whole blood following controlled single‐dose intranasal COC administration. 相似文献
999.
Aoki Takuya Yamamoto Yosuke Ikenoue Tatsuyoshi Fukuhara Shunichi 《International journal of clinical pharmacy》2019,41(2):531-537
International Journal of Clinical Pharmacy - Background Deprescribing is a patient-centered intervention with inherent uncertainties and requires shared decision making and patient involvement.... 相似文献
1000.
Michinori Ogura Kiyoshi Ando Tatsuya Suzuki Kenichi Ishizawa Sung Yong Oh Kuniaki Itoh Kazuhito Yamamoto Wing Yan Au Hwei‐Fang Tien Yoshihiro Matsuno Takashi Terauchi Keiko Yamamoto Masahiko Mori Yoshinobu Tanaka Takashi Shimamoto Kensei Tobinai Won Seog Kim 《British journal of haematology》2014,165(6):768-776
Although initial rituximab‐containing chemotherapies achieve high response rates, indolent B‐cell non‐Hodgkin lymphoma (B‐NHL), such as follicular lymphoma (FL), is still incurable. Therefore, new effective agents with novel mechanisms are anticipated. In this multicentre phase II study, patients with relapsed/refractory indolent B‐NHL and mantle cell lymphoma (MCL) received vorinostat 200 mg twice daily for 14 consecutive days in a 21‐d cycle until disease progression or unacceptable toxicity occurred. The primary endpoint was overall response rate (ORR) in FL patients and safety and tolerability in all patients. Secondary endpoints included progression‐free survival (PFS). Fifty‐six eligible patients were enrolled; 50 patients (39 with FL, seven with other B‐NHL, and four with MCL) were evaluable for ORR, and 40 patients had received rituximab‐containing prior chemotherapeutic regimens. For the 39 patients with FL, the ORR was 49% [95% confidence interval (CI): 32·4, 65·2] and the median PFS was 20 months (95% CI: 11·2, 29·7). Major toxicities were manageable grade 3/4 thrombocytopenia and neutropenia. Vorinostat offers sustained antitumour activity in patients with relapsed or refractory FL with an acceptable safety profile. Further investigation of vorinostat for clinical efficacy is warranted. 相似文献